$VIRX
Viracta Therapeutics, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022009031 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.181M $4.336M $4.015M
YoY Change 8.01% 12.92% 12.78%
% of Gross Profit
Research & Development $6.324M $6.096M $7.303M
YoY Change 16.12% 51.49% 242.86%
% of Gross Profit
Depreciation & Amortization $54.00K $54.00K $59.00K
YoY Change 14.89% 237.5%
% of Gross Profit
Operating Expenses $10.51M $10.43M $11.32M
YoY Change 12.75% -88.7% 98.91%
Operating Profit -$10.51M -$10.43M
YoY Change 12.75% -86.77%
Interest Expense -$77.00K $124.0K -$129.0K
YoY Change -163.11% 18.1%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$10.58M -$10.55M -$11.45M
YoY Change 15.4% -86.69% 137.98%
Income Tax
% Of Pretax Income
Net Earnings -$10.58M -$10.55M -$11.45M
YoY Change 15.4% -86.69% 137.98%
Net Earnings / Revenue
Basic Earnings Per Share -$0.28 -$0.28
Diluted Earnings Per Share -$281.4K -$281.0K -$305.3K
COMMON SHARES
Basic Shares Outstanding 37.49M 37.49M 37.31M
Diluted Shares Outstanding 37.60M 37.54M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $83.15M $92.20M $103.6M
YoY Change -32.25% -28.64% 407.62%
Cash & Equivalents $81.58M $92.20M $103.6M
Short-Term Investments $1.562M
Other Short-Term Assets $3.220M $3.174M $1.719M
YoY Change 33.0% 2.39% 1.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $86.37M $95.37M $105.3M
YoY Change -30.99% -27.91% 123.04%
LONG-TERM ASSETS
Property, Plant & Equipment $676.0K $210.0K $242.0K
YoY Change 1548.78% 425.0% 450.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.114M $2.255M $2.397M
YoY Change -21.12% -20.23% 3053.95%
Total Long-Term Assets $2.790M $3.014M $3.279M
YoY Change -21.12% -22.82% 196.47%
TOTAL ASSETS
Total Short-Term Assets $86.37M $95.37M $105.3M
Total Long-Term Assets $2.790M $3.014M $3.279M
Total Assets $89.16M $98.39M $108.6M
YoY Change -30.72% -27.77% 124.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.826M $3.222M $2.901M
YoY Change -28.84% 105.09% 86.32%
Accrued Expenses $5.395M $4.152M $5.802M
YoY Change 68.8% 14.13% 72.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $7.221M $7.766M $9.084M
YoY Change 3.85% 23.96% 44.56%
LONG-TERM LIABILITIES
Long-Term Debt $4.860M $4.841M $4.819M
YoY Change 16.97% 4.49% 15.98%
Other Long-Term Liabilities $71.00K $175.0K $278.0K
YoY Change -85.02% -70.83%
Total Long-Term Liabilities $4.931M $4.841M $4.819M
YoY Change 18.68% 4.49% 15.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.221M $7.766M $9.084M
Total Long-Term Liabilities $4.931M $4.841M $4.819M
Total Liabilities $12.15M $12.61M $13.90M
YoY Change 9.4% 15.68% 33.18%
SHAREHOLDERS EQUITY
Retained Earnings -$176.2M -$165.7M
YoY Change 35.39% 225.4%
Common Stock $4.000K $4.000K
YoY Change 0.0% 300.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.00M $85.61M $94.37M
YoY Change
Total Liabilities & Shareholders Equity $89.16M $98.39M $108.6M
YoY Change -30.72% -27.77% 124.72%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$10.58M -$10.55M -$11.45M
YoY Change 15.4% -86.69% 137.98%
Depreciation, Depletion And Amortization $54.00K $54.00K $59.00K
YoY Change 14.89% 237.5%
Cash From Operating Activities -$9.034M -$11.36M -$7.211M
YoY Change 37.04% -545.43% 27.4%
INVESTING ACTIVITIES
Capital Expenditures -$44.00K -$19.00K
YoY Change 780.0%
Acquisitions
YoY Change
Other Investing Activities -$1.562M $0.00 $0.00
YoY Change -52166.67% -100.0%
Cash From Investing Activities -$1.606M $0.00 -$19.00K
YoY Change 80200.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.000K
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.00K 8.000K -199.0K
YoY Change -82.35% -99.99% -1095.0%
NET CHANGE
Cash From Operating Activities -9.034M -11.36M -7.211M
Cash From Investing Activities -1.606M 0.000 -19.00K
Cash From Financing Activities 24.00K 8.000K -199.0K
Net Change In Cash -10.62M -11.36M -7.429M
YoY Change 64.39% -113.83% 31.72%
FREE CASH FLOW
Cash From Operating Activities -$9.034M -$11.36M -$7.211M
Capital Expenditures -$44.00K -$19.00K
Free Cash Flow -$8.990M -$7.192M
YoY Change 36.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001061027
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
000-51531
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
VIRACTA THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3295878
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2533 S. Coast Hwy. 101, Suite 210
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cardiff
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92007
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
400-8470
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
VIRX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37488274
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92199000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103554000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3174000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1719000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
95373000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
105273000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37424863
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
210000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
549000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
640000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2255000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2397000
CY2022Q1 us-gaap Assets
Assets
98387000
CY2021Q4 us-gaap Assets
Assets
108552000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3222000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2901000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4152000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5802000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
392000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
381000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7766000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9084000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4841000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4819000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
175000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
278000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10248
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10248
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
5452000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
5452000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37486177
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37486177
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37424863
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
256372000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
254592000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176223000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165677000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
85605000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
94371000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98387000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108552000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6096000
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4024000
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
84478000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4336000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3840000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
10432000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
92342000
CY2022Q1 virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
CY2021Q1 virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
13500000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10432000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-78842000
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
10000
CY2021Q1 us-gaap Interest Income Other
InterestIncomeOther
6000
CY2022Q1 us-gaap Interest Expense
InterestExpense
124000
CY2021Q1 us-gaap Interest Expense
InterestExpense
105000
CY2022Q1 us-gaap Other Expenses
OtherExpenses
0
CY2021Q1 us-gaap Other Expenses
OtherExpenses
290000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-114000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-389000
CY2022Q1 virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-10546000
CY2021Q1 virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-79231000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.22
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37535874
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15166737
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
94371000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022Q1 virx Vestingofearlyexerciseofstockoptions
Vestingofearlyexerciseofstockoptions
1
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1772000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10546000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
85605000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-46200000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2021Q1 virx Vestingofearlyexerciseofstockoption
Vestingofearlyexerciseofstockoption
1000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
62317000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
97982000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
83302000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
396000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
5452000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
644000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-79231000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
124744000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10546000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-79231000
CY2022Q1 virx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
CY2021Q1 virx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
84478000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1772000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
644000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16000
CY2022Q1 virx Change In Fair Value Of Preferred Stock Warrant Liability
ChangeInFairValueOfPreferredStockWarrantLiability
0
CY2021Q1 virx Change In Fair Value Of Preferred Stock Warrant Liability
ChangeInFairValueOfPreferredStockWarrantLiability
290000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1455000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2447000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-142000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-455000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
321000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-409000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1650000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1250000
CY2022Q1 virx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1000
CY2021Q1 virx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
5000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11363000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2551000
CY2022Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2021Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
17143000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17143000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62317000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
81000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62398000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11355000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
82092000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103554000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47089000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92199000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129181000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
102000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
84000
CY2022Q1 virx Warrant Liability Reclassification To Equity
WarrantLiabilityReclassificationToEquity
0
CY2021Q1 virx Warrant Liability Reclassification To Equity
WarrantLiabilityReclassificationToEquity
396000
CY2022Q1 virx Issuance Of Convertible Preferred Stock Noncash Transaction Upon Merger
IssuanceOfConvertiblePreferredStockNoncashTransactionUponMerger
0
CY2021Q1 virx Issuance Of Convertible Preferred Stock Noncash Transaction Upon Merger
IssuanceOfConvertiblePreferredStockNoncashTransactionUponMerger
5452000
CY2022Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2021Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
83302000
CY2022Q1 virx Issuance Of Common Stock Noncash Transaction Upon Merger
IssuanceOfCommonStockNoncashTransactionUponMerger
0
CY2021Q1 virx Issuance Of Common Stock Noncash Transaction Upon Merger
IssuanceOfCommonStockNoncashTransactionUponMerger
97982000
CY2022Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1119
CY2022Q1 virx Percentage Of Outstanding Common Stock Of Combined Company
PercentageOfOutstandingCommonStockOfCombinedCompany
0.86
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
65000000.0
CY2021Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
3.5-for-one
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176200000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92200000
CY2022Q1 virx Working Capital
WorkingCapital
87600000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</span></p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></p>
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6593071
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4582827
CY2021Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
50000000.0
CY2021Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
45000000.0
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
842000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1695000
CY2022Q1 virx Accrued Clinical Trial And Contract Expenses
AccruedClinicalTrialAndContractExpenses
2711000
CY2021Q4 virx Accrued Clinical Trial And Contract Expenses
AccruedClinicalTrialAndContractExpenses
3380000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
217000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
180000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
382000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
547000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4152000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5802000
CY2022Q1 us-gaap Line Of Credit Facility Borrowing Capacity Description
LineOfCreditFacilityBorrowingCapacityDescription
The second tranche of $20.0 million would be available upon request by the Company and Lenders approval until August 31, 2022, and the third tranche, $25.0 million, would be available at the Company's request subject Lenders' discretion. As of March 31, 2022, neither tranche had been requested.
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1714000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1714000
CY2022Q1 virx Long Term Debt Maturities Repayments Of Principal After Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearThree
1572000
CY2022Q1 virx Aggregate Minimum Payments Under Debt Arrangements
AggregateMinimumPaymentsUnderDebtArrangements
5000000
CY2022Q1 virx Unamortized Discount Of Future Minimum Payments Under Long Term Debt Arrangement
UnamortizedDiscountOfFutureMinimumPaymentsUnderLongTermDebtArrangement
159000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4841000
CY2022Q1 us-gaap Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1
BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
103400000
CY2022Q1 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
1600000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18956000
CY2022Q1 virx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Acquired Ipr And D Projects
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredIprAndDProjects
84478000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
103434000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
17143000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
3768000
CY2022Q1 virx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities
1955000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18956000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37486177
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37424863
CY2022Q1 us-gaap Shares Issued
SharesIssued
0
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
18811552
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8240586
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6429819
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1772000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
644000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
567000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
175000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
53000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.22
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
549000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
105000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.902
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3964000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.33
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
1605000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.03
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.96
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
62000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.27
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5500000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.13
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
745000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.22
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
692000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.22
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y2M12D
CY2022Q1 virx Fair Value Of Shares Issuable Under Employee Stock Purchase Plan
FairValueOfSharesIssuableUnderEmployeeStockPurchasePlan
25000
CY2020Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
option for an additional year
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
104000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
71000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
99000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D

Files In Submission

Name View Source Status
0000950170-22-009031-index-headers.html Edgar Link pending
0000950170-22-009031-index.html Edgar Link pending
0000950170-22-009031.txt Edgar Link pending
0000950170-22-009031-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
virx-20220331.htm Edgar Link pending
virx-20220331.xsd Edgar Link pending
virx-20220331_cal.xml Edgar Link unprocessable
virx-20220331_def.xml Edgar Link unprocessable
virx-20220331_htm.xml Edgar Link completed
virx-20220331_lab.xml Edgar Link unprocessable
virx-20220331_pre.xml Edgar Link unprocessable
virx-ex31_1.htm Edgar Link pending
virx-ex31_2.htm Edgar Link pending
virx-ex32_1.htm Edgar Link pending
virx-ex32_2.htm Edgar Link pending